Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia
X. Wang,H. Chao-Su,Y. Hong-Mei,H. Xia-Yun,Z. Guo-Pei
DOI: https://doi.org/10.1016/j.ijrobp.2013.06.497
2013-01-01
Abstract:Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia.Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years.ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up.ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. Patients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. From January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. IMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline.